How has SI-BONE's domestic project growth impacted its revenue in Q4 2024?

**SI-BONE's domestic project growth has significantly contributed to its revenue in Q4 2024.** Here's the analysis:

1. **Market Expansion**: SI-BONE has been expanding its market presence, especially in the U.S., which has shown strong growth in revenue. The company reported a 19% year-over-year growth in total revenue, with U.S. revenue reaching $38.3 million, an 18% increase compared to the previous year.
2. **Product Portfolio**: The company's focus on minimally invasive surgical solutions with its iFuse Implant System has been successful, leading to increased adoption among surgeons. This has resulted in a 15% year-over-year increase in active U.S. surgeons using their system, indicating broader acceptance of their technology.
3. **Sales Productivity**: Sales representatives' productivity improved by 21% year-over-year, suggesting effective sales strategies and growing demand for SI-BONE's products.
4. **International Partnerships**: Recent partnerships, such as Osteotec's exclusive distribution agreement for Cerapedics' products in the UK and Ireland, and the re-launch of the Osteotec Silicone Finger Implant in markets accepting CE-marked medical devices, are expected to drive global sales and increase market access, potentially impacting Q4 2024 revenue positively.

In conclusion, SI-BONE's domestic project growth, bolstered by market expansion, product innovation, effective sales strategies, and international partnerships, has likely had a substantial impact on its revenue in Q4 2024, contributing to the company's overall growth and market position.